Research

Hormonal

Metformin treatment (1-2 g/day) improves hyperandrogenism, hyperinsulinemia, and menstrual cyclicity in nonobese women with PCOS primarily by increasing hepatic insulin clearance and reducing abdominal adiposity, without significantly altering whole-body insulin sensitivity.

For nonobese women with PCOS, metformin (1-2g/day) can effectively lower testosterone and improve menstrual cycles by helping the liver clear insulin faster, rather than by changing how muscles use glucose. This suggests that even without weight loss or improved muscle sensitivity, hormonal balance can be restored.

GoodSupportsHIGH confidence
Metformin improved hyperandrogenism, hyperinsulinemia, and menstrual cyclicity, most likely through its positive effect on insulin clearance and abdominal adiposity. Thus, similarly to obese PCOS women, nonobese PCOS subjects with anovulation may also benefit from metformin treatment.
Laure Morin‐Papunen et al. · The Journal of Clinical Endocrinology & Metabolism · 2003

Why this rating

Randomized controlled trial comparing active treatment to standard care, though sample size is small (n=17).

Source

Metformin<i>Versus</i>Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study

Laure Morin‐Papunen et al. · The Journal of Clinical Endocrinology & Metabolism · 2003

DOI 10.1210/jc.2002-020997

rct · n=17Cited 182×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →